Cantor Fitzgerald Boosts Earnings Estimates for SI-BONE

SI-BONE, Inc. (NASDAQ:SIBN) – Research analysts at Cantor Fitzgerald increased their FY2024 EPS estimates for SI-BONE in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.69) per share for the year, up from their previous estimate of ($0.95). The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

Other analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a report on Wednesday, November 13th. Truist Financial upped their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Morgan Stanley cut their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SI-BONE currently has an average rating of “Buy” and an average target price of $23.00.

SI-BONE Trading Up 3.9 %

SIBN opened at $12.92 on Monday. The stock has a market capitalization of $541.86 million, a PE ratio of -14.04 and a beta of 1.22. The firm’s fifty day moving average price is $14.03 and its 200 day moving average price is $14.29. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 8.12. SI-BONE has a 12-month low of $11.76 and a 12-month high of $21.70.

Insiders Place Their Bets

In other SI-BONE news, insider Anthony J. Recupero sold 3,305 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the sale, the insider now directly owns 233,412 shares of the company’s stock, valued at approximately $3,169,734.96. This represents a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 5,060 shares of company stock valued at $72,621. Company insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of SI-BONE by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock worth $12,921,000 after acquiring an additional 30,005 shares during the period. Barclays PLC increased its holdings in shares of SI-BONE by 190.8% in the 3rd quarter. Barclays PLC now owns 96,623 shares of the company’s stock worth $1,350,000 after acquiring an additional 63,402 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of SI-BONE in the 3rd quarter worth about $448,000. Pier Capital LLC increased its holdings in shares of SI-BONE by 23.6% in the 3rd quarter. Pier Capital LLC now owns 465,898 shares of the company’s stock worth $6,513,000 after acquiring an additional 88,897 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of SI-BONE by 29.0% in the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock worth $1,081,000 after acquiring an additional 17,410 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.